Treatment Options for BCG-Unresponsive NMIBC: Balancing Efficacy, Logistics, and Patient Preferences

In the second segment of this roundtable, Roger Li, MD, Vitaly Margulis, MD, Kyle Rose, MD, and Paul Crispen, MD, explore the evolving landscape of treatments for BCG-unresponsive bladder cancer. The conversation covers the challenges of balancing efficacy, toxicity, and patient preferences while addressing innovative therapies like gem/doce, adstiladrin, and pembrolizumab. Practical insights into clinical trials, patient-specific considerations, and the role of cystectomy as the gold standard are highlighted, offering valuable guidance for practitioners in this complex therapeutic space.

#bladdercancer #urology #cancer #cancerresearch #healthcare

Видео Treatment Options for BCG-Unresponsive NMIBC: Balancing Efficacy, Logistics, and Patient Preferences канала GU Oncology Now